Evidence map›Paper›PMID 36388269›Full record

ArticleFrontiers in public health2022

Clinical significance of novel biomarkers to predict the natural course of hepatitis B infection.

Weikang Wu, Xiaojie Yuan, Weilu Zhang, Haowei Zhou, Xiangyu Kong, Zhen He, Ting Fu, Wenhua Zhang, Wenling Jia, Chunhui Liang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 13 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Weikang WuMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Xiaojie YuanMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Weilu ZhangMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Haowei ZhouMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Xiangyu KongMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Zhen HeMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Ting FuMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Wenhua ZhangHepatobiliary Center, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.
Wenling JiaHepatobiliary Center, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.
Chunhui LiangHepatobiliary Center, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.
Haitao TangHepatobiliary Center, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.
Fengmei WangHepatobiliary Center, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.
Yancheng YeClinical Drug Experiment Institution, Wuwei Cancer Hospital of Gansu Province, Wuwei, China.
Zhongjun ShaoMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Zhaohua JiMinistry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Department of Epidemiology, School of Public Health, Air Force Medical University, Xi'an, China.
Air Force Medical University · CNHuawei Technologies (China) · CNGansu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim: Chronic hepatitis B (CHB) can be divided into immune tolerance (IT), immune clearance (IC), hepatitis B e antigen (HBeAg)-negative inactive/quiescent carrier (ENQ), and HBeAg-negative hepatitis (ENH) phases. The conventional biomarkers used to distinguish these phases have limitations. We examined the clinical significance of hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) as novel biomarkers. Methods: One hundred eighty-nine patients without treatment currently were categorized by CHB phase (IT = 46, IC = 45, ENQ = 49, ENH = 49). The associations of HBV RNA and HBcrAg with HBV DNA and alanine transaminase (ALT) were analyzed. The decision tree model was used to distinguish the four phases in the natural course of CHB. Results: The concentrations of HBV RNA and HBcrAg were highest in the IT and IC phases ( Conclusion: Serum HBV RNA and HBcrAg may be useful to monitor CHB progression.

Indexed as

Hepatitis BHepatitis B, ChronicBiomarkersDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHumansRNABiomarkersDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensRNAHBcrAgHBV DNAHBV RNAhepatitis Bnovel biomarkersphase

Identifiers

PMID36388269
PMCPMC9650535
OpenAlexW4307462461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.